$SPPI Just checked the website of Hamni. What I noticed now is that poziotinib not only has our well known catalysts with ODAC Meeting September 22-23 and PDUFA date November 24 (regarding previously treated NSCLC patients harboring HER2 exon 20 insertion mutations), but also is in phase 2 as 1st-line therapy in NSCLC. There is nothing in the current SPPI presentation. Or I didn't read it carefully....
1
5
5 Likes